Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Determining the minimum clinically important differences for outcomes in the DOMINO trial.

Howard R, Phillips P, Johnson T, O'Brien J, Sheehan B, Lindesay J, Bentham P, Burns A, Ballard C, Holmes C, McKeith I, Barber R, Dening T, Ritchie C, Jones R, Baldwin A, Passmore P, Findlay D, Hughes A, Macharouthu A, Banerjee S, Jones R, Knapp M, Brown RG, Jacoby R, Adams J, Griffin M, Gray R.

Int J Geriatr Psychiatry. 2011 Aug;26(8):812-7. doi: 10.1002/gps.2607. Epub 2010 Sep 16.

PMID:
20848576
2.

DOMINO-AD protocol: donepezil and memantine in moderate to severe Alzheimer's disease - a multicentre RCT.

Jones R, Sheehan B, Phillips P, Juszczak E, Adams J, Baldwin A, Ballard C, Banerjee S, Barber B, Bentham P, Brown R, Burns A, Dening T, Findlay D, Gray R, Griffin M, Holmes C, Hughes A, Jacoby R, Johnson T, Jones R, Knapp M, Lindesay J, McKeith I, McShane R, Macharouthu A, O'Brien J, Onions C, Passmore P, Raftery J, Ritchie C, Howard R; DOMINO-AD team.

Trials. 2009 Jul 24;10:57. doi: 10.1186/1745-6215-10-57.

3.

Donepezil and memantine for moderate-to-severe Alzheimer's disease.

Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P.

N Engl J Med. 2012 Mar 8;366(10):893-903. doi: 10.1056/NEJMoa1106668.

4.

A responder analysis of memantine treatment in patients with Alzheimer disease maintained on donepezil.

van Dyck CH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group.

Am J Geriatr Psychiatry. 2006 May;14(5):428-37.

PMID:
16670247
5.

Effectiveness of adding memantine to an Alzheimer dementia treatment regimen which already includes stable donepezil therapy: a critically appraised topic.

Riordan KC, Hoffman Snyder CR, Wellik KE, Caselli RJ, Wingerchuk DM, Demaerschalk BM.

Neurologist. 2011 Mar;17(2):121-3. doi: 10.1097/NRL.0b013e31820aa383.

PMID:
21364371
6.

Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.

Santoro A, Siviero P, Minicuci N, Bellavista E, Mishto M, Olivieri F, Marchegiani F, Chiamenti AM, Benussi L, Ghidoni R, Nacmias B, Bagnoli S, Ginestroni A, Scarpino O, Feraco E, Gianni W, Cruciani G, Paganelli R, Di Iorio A, Scognamiglio M, Grimaldi LM, Gabelli C, Sorbi S, Binetti G, Crepaldi G, Franceschi C.

CNS Drugs. 2010 Feb;24(2):163-76. doi: 10.2165/11310960-000000000-00000.

PMID:
20088621
7.

Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.

Feldman HH, Schmitt FA, Olin JT; Memantine MEM-MD-02 Study Group.

Alzheimer Dis Assoc Disord. 2006 Oct-Dec;20(4):263-8.

PMID:
17132971
8.

Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.

Feldman H, Gauthier S, Hecker J, Vellas B, Xu Y, Ieni JR, Schwam EM; Donepezil MSAD Study Investigators Group.

Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69.

PMID:
15920715
9.

Cholinesterase inhibitors for dementia with Lewy bodies, Parkinson's disease dementia and cognitive impairment in Parkinson's disease.

Rolinski M, Fox C, Maidment I, McShane R.

Cochrane Database Syst Rev. 2012 Mar 14;(3):CD006504. doi: 10.1002/14651858.CD006504.pub2. Review.

PMID:
22419314
10.

A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.

Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, Whalen E.

J Am Geriatr Soc. 2001 Dec;49(12):1590-9.

PMID:
11843990
11.

The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review and economic model.

Bond M, Rogers G, Peters J, Anderson R, Hoyle M, Miners A, Moxham T, Davis S, Thokala P, Wailoo A, Jeffreys M, Hyde C.

Health Technol Assess. 2012;16(21):1-470. doi: 10.3310/hta16210. Review.

12.

A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.

Di Santo SG, Prinelli F, Adorni F, Caltagirone C, Musicco M.

J Alzheimers Dis. 2013;35(2):349-61. doi: 10.3233/JAD-122140. Review.

PMID:
23411693
13.
14.

Memantine versus donepezil in mild to moderate Alzheimer's disease: a randomized trial with magnetic resonance spectroscopy.

Modrego PJ, Fayed N, Errea JM, Rios C, Pina MA, Sarasa M.

Eur J Neurol. 2010 Mar;17(3):405-12. doi: 10.1111/j.1468-1331.2009.02816.x. Epub 2009 Oct 28.

PMID:
19874395
16.

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease.

Waldemar G, Hyvärinen M, Josiassen MK, Kørner A, Lehto H, Wetterberg P.

Int J Geriatr Psychiatry. 2008 Sep;23(9):979-81. doi: 10.1002/gps.1979. No abstract available.

PMID:
18229874
17.

A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer's disease.

Feldman H, Gauthier S, Hecker J, Vellas B, Subbiah P, Whalen E; Donepezil MSAD Study Investigators Group.

Neurology. 2001 Aug 28;57(4):613-20. Erratum in: Neurology 2001 Dec 11;57(11):2153.

PMID:
11524468
18.

Cholinesterase inhibitors for Alzheimer's disease.

Birks J.

Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. Review.

19.

Donepezil in severe Alzheimer's disease.

Winblad B.

Am J Alzheimers Dis Other Demen. 2009 Jun-Jul;24(3):185-92. doi: 10.1177/1533317509332094. Review.

PMID:
19246572
20.

Systematic review of measures of clinical significance employed in randomized controlled trials of drugs for dementia.

Molnar FJ, Man-Son-Hing M, Fergusson D.

J Am Geriatr Soc. 2009 Mar;57(3):536-46. doi: 10.1111/j.1532-5415.2008.02122.x. Epub 2009 Jan 29. Review.

PMID:
19187414

Supplemental Content

Support Center